公开(公告)号：EP2204179A3

公开(公告)日：2010-12-22

申请号：EP10158052.0

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL·12.

公开(公告)号：EP2204180A2

公开(公告)日：2010-07-07

申请号：EP10158054.6

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K35/76 ,  A61K39/00 ,  A61K39/245 ,  A61K39/285 ,  C12N7/00 ,  C12N15/863

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

摘要翻译： 本发明涉及使用病毒制备用于接种或治疗新生儿或产前动物（包括人）的药物，其中所述病毒能够感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人类）中复制为感染性后代病毒。 该病毒优选是改良的安卡拉痘苗病毒。 具体地说，本发明涉及新生儿接种疫苗以防止与用于疫苗接种的病毒属于同一病毒组的病毒感染。 此外，本发明涉及新生儿针对选自外来抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明进一步涉及如上定义的病毒用于增加激活树突细胞或其前体细胞和/或增加树突细胞或其前体细胞数量和/或增加产生和/或细胞的因子水平 干扰素（IFN）或IL-12的含量。

公开(公告)号：EP2204180A3

公开(公告)日：2010-12-22

申请号：EP10158054.6

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K39/285 ,  A61K39/245

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

公开(公告)号：EP2204179A2

公开(公告)日：2010-07-07

申请号：EP10158052.0

申请日：2003-04-16

申请人： Bavarian Nordic A/S

发明人： Chaplin, Paul ,  Suter, Mark ,  Ackermann, Mathias ,  Franchini, Marco ,  Vollstedt, Sabine ,  Hefti, Hans-Peter

IPC分类号： A61K35/76 ,  A61K39/00 ,  A61K39/245 ,  A61K39/285 ,  C12N7/00 ,  C12N15/863

CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/55 ,  A61K2039/58 ,  C12N7/00 ,  C12N2710/16634 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2710/24161 ,  Y02A50/386 ,  Y02A50/39 ,  Y02A50/394

摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.
In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL·12.

摘要翻译： 本发明涉及使用病毒制备用于接种或治疗新生儿或产前动物（包括人）的药物，其中所述病毒能够感染新生儿或产前动物（包括人）的细胞， 但不能在新生儿或产前动物（包括人类）中复制为感染性后代病毒。 该病毒优选是改良的安卡拉痘苗病毒。 具体地说，本发明涉及新生儿接种疫苗以防止与用于疫苗接种的病毒属于同一病毒组的病毒感染。 此外，本发明涉及新生儿针对选自外来抗原和肿瘤抗原的抗原的疫苗接种，其中肿瘤抗原和/或外源抗原不同于与病毒相关的抗原。 本发明进一步涉及如上定义的病毒用于增加激活树突细胞或其前体细胞和/或增加树突细胞或其前体细胞数量和/或增加产生和/或细胞的因子水平 干扰素（IFN）或IL·12的含量。